The impact of CYP2C19*2, CYP4F2*3, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated with dual antiplatelet therapy

  • Vacis Tatarunas, Nora Kupstyte, Agne Giedraitiene, Vilius Skipskis, Valdas Jakstas, Vaidotas Zvikas, Vaiva Lesauskaite
  • Blood Coagulation & Fibrinolysis, December 2017, Wolters Kluwer Health
  • DOI: 10.1097/mbc.0000000000000658

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1097/mbc.0000000000000658

The following have contributed to this page: Vaidotas Žvikas